Studies from IRCCS Regina Elena National Cancer Institute Update Current Data on Mesotheliomas (Dhea-s, Androstenedione, 17-8-estradiol Signature As Novel Biomarkers for Early Prediction of Risk of Malignant Pleural Mesothelioma Linked To...).

A recent study conducted in Rome, Italy explored the use of certain biomarkers for the early diagnosis of mesothelioma, a type of cancer. The study analyzed the levels of 17-8-estradiol, DHEA-S, and androstenedione in the serum of mesothelioma patients, asbestos-exposed healthy subjects, and non-asbestos-exposed healthy subjects. The results showed significant differences in 17-8-estradiol levels between mesothelioma patients and both groups of healthy subjects, suggesting its potential as an early diagnostic marker. The study also found variations in androstenedione and DHEA-S levels between asbestos-exposed and non-asbestos-exposed individuals. The researchers concluded that these biomarkers could aid in the early prediction and diagnosis of mesothelioma in asbestos-exposed individuals. [Extracted from the article]